Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Autologous bone marrow transplantation for children with AML in first remission

Bone Marrow Transplantation volume 40, pages 313–318 (2007)Cite this article

Abstract

In Children's cancer group (CCG) 2891, newly diagnosed patients with AML were randomized between standard and intensive timing induction therapies. Patients in first remission who lacked an HLA matched family donor were randomized between an autologous bone marrow transplantation (ABMT) where marrow was purged with 4 hydroperoxycyclophosphamide and consolidation chemotherapy. One hundred and thirty seven patients received an ABMT. Myeloid and platelet engraftment occurred at a median of 44 and 42 days, respectively. Disease-free survival (DFS), relapse-free survival and overall survival at 8 years post induction were 47% (95% confidence interval (CI): 38–55), 50% (CI: 42–59) and 55% (CI: 46–63), respectively. Multivariate analysis of DFS showed WBC <50 000/μl and having received intensively timed induction therapy were associated with improved DFS. Recipients who received intensive timed induction therapy and whose WBC was less than 50 000/μl had a DFS at 8 years of 62% (CI: 49–73). Conversely, recipients who received intensive timed induction therapy patients whose WBC was ⩾50 000/μl had a DFS of 33% (CI: 17–50), P=0.003. The results confirm previous studies that ABMT is effective post remission therapy for pediatric patients with AML in first remission.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87: 4979–4989.

    CAS  PubMed  Google Scholar 

  2. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56–62.

    Article  CAS  Google Scholar 

  3. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428–1434.

    Article  CAS  Google Scholar 

  4. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046–1054.

    Article  CAS  Google Scholar 

  5. Bonetti F, Zecca M, Pession A, Messina C, Montagna D, Lanino E et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol 1999; 17: 3729–3733.

    Article  CAS  Google Scholar 

  6. Vignetti M, Rondelli R, Locatelli F, Lanino E, Miniero R, Rossetti F et al. Autologous bone marrow transplantation in children with acute myeloblastic leukemia: Report from the Italian National Pediatric Registry (AIEOP-BMT). Bone Marrow Transplant 1996; 18 (Suppl 2): 59–62.

    PubMed  Google Scholar 

  7. Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H . Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993; 82: 3730–3738.

    CAS  PubMed  Google Scholar 

  8. Ball ED, Wilson J, Phelps V, Neudorf S . Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up. Bone Marrow Transplant 2000; 25: 823–829.

    Article  CAS  Google Scholar 

  9. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4 hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141–147.

    Article  CAS  Google Scholar 

  10. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 475–481.

    Article  Google Scholar 

  11. Kalbfleish JD, Prentice RL . The Statistical Analysis of Failure Time Data, 2nd edn. John Wiley & Sons: Hoboken, NJ, USA, 2002.

    Book  Google Scholar 

  12. Sposto R . Cure model analysis in cancer: an application to data from the Children's Cancer Group. Stat Med 2002; 21: 293–312.

    Article  Google Scholar 

  13. Hassan M, Ljungman P, Bolme P, Ringden O, Syrckova Z, Bekassy A et al. Busulfan bioavailability. Blood 1994; 84: 2144–2150.

    CAS  PubMed  Google Scholar 

  14. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030–1034.

    CAS  PubMed  Google Scholar 

  15. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–3060.

    CAS  Google Scholar 

  16. Blaise D, Maraninchi D, Michallet M, Reiffers J, Jouet JP, Milpied N et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669–3671.

    Article  CAS  Google Scholar 

  17. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation – a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994; 12: 1217–1222.

    Article  CAS  Google Scholar 

  18. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723–2730.

    CAS  PubMed  Google Scholar 

  19. Socié G, Clift R, Blaise D, Devergie A, Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569–3574.

    Article  Google Scholar 

  20. Woolfrey A, Gooley T, Sievers E, Milner LA, Andrews RG, Walters M et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998; 92: 3546–3556.

    CAS  PubMed  Google Scholar 

  21. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro Jr J, Anderson WF et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–89.

    Article  CAS  Google Scholar 

  22. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–1614.

    CAS  PubMed  Google Scholar 

  23. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506–1513.

    Article  CAS  Google Scholar 

  24. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Tjoa T et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6 (Suppl 1): S39–S44.

    PubMed  Google Scholar 

  25. Steins M, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839.

    Article  CAS  Google Scholar 

  26. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al., Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children's Hospital of Orange County, Orange, CA, USA

    S Neudorf

  2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    J Sanders

  3. Roger Maris Cancer Center, Fargo, ND, USA

    N Kobrinsky

  4. University of Southern California Keck School of Medicine, Los Angeles, CA, USA

    T A Alonzo, J D Buckley & W Howells

  5. Children's Oncology Group, Bethesda, MD, USA

    A Buxton

  6. University of North Carolina, Chapel Hill, NC, USA

    S Gold

  7. Izaak W Killam Hospital for Children, Halifaz, Nova Scotia, Canada

    D R Barnard

  8. Miller Children's Hospital/Harbor-UCLA, Long Beach, CA, USA

    J DeSwarte

  9. British Columbia's Children's Hospital, Vancouver, British Columbia, Canada

    D Kalousek

  10. Children's Hospital of Philadelphia, Philadelphia, PA, USA

    B J Lange

  11. Aflac Cancer Center, Emory University, Atlanta, GA, USA

    W G Woods

Authors
  1. S Neudorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Sanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Kobrinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T A Alonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Buxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J D Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Howells
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D R Barnard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J DeSwarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Kalousek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B J Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. W G Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Neudorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neudorf, S., Sanders, J., Kobrinsky, N. et al. Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplant 40, 313–318 (2007). https://doi.org/10.1038/sj.bmt.1705680

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705680

Keywords

This article is cited by

Search

Advanced search

Quick links